The DOI matches its Crossref record.
Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Open accessAbstract
BACKGROUND: The long duration of the current tuberculosis (TB) treatment is demanding and warrants the development of new drugs. Moxifloxacin shows promising results and may be combined with rifampicin to shorten the duration of TB treatment. Rifampicin induces the phase II metabolic enzymes that are involved in the biotransformation of moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin should be investigated. PATIENTS AND METHODS: Nineteen Indonesian patients with pulmonary TB who were in the last month of their TB treatment completed a 1-arm, 2-period, fixed-order pharmacokinetic study. In phase 1 of the study, they received 400 mg of moxifloxacin every day for 5 days in addition to 450 mg of rifampicin and 600 mg of isoniazid 3 times per week. In phase 2 of the study, after a 1-month washout period, patients received moxifloxacin for another 5 days (without rifampicin and isoniazid). A 24-h pharmacokinetic curve for moxifloxacin was recorded on the last day of both study periods, and its pharmacokinetic parameters were evaluated for an interaction with rifampicin, using a bioequivalence approach. RESULTS: Coadministration of moxifloxacin with rifampicin and isoniazid resulted in an almost uniform decrease in moxifloxacin exposure (in 18 of 19 patients). The geometric means for the ratio of phase 1 area under the curve to phase 2 area under the curve and for the ratio of phase 1 peak plasma concentration to phase 2 peak plasma concentration were 0.69 (90% confidence interval, 0.65-0.74) and 0.68 (90% confidence interval, 0.64-0.73), respectively. The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1 h to 2.5 h when combined with rifampicin and isoniazid (P=.003). CONCLUSIONS: Coadministration of moxifloxacin with intermittently administered rifampicin and isoniazid results in reduced moxifloxacin plasma concentrations, which is most likely the result of induced glucuronidation or sulphation by rifampicin. Further studies are warranted to evaluate the impact of the interaction on the outcome of TB treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Self-citationResistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
van Ingen, J., Boeree, M. J., van Soolingen, D., & Mouton, J. W. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.04.001 · Cited by 351
Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Borm, G., Aarnoutse, R. E., & van Crevel, R. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70264-5 · Cited by 344
Self-citation
Metadata
- Authors
- Nijland, H. M. J., Ruslami, R., Suroto, A. J., Burger, D. M., Alisjahbana, B., van Crevel, R., & Aarnoutse, R. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-15
- Volume
- 45
- Issue
- 8
- Pages
- 1001-1007
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2096624362
- Cited by
- 166
- References
- 0
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis. https://app.cochat.ai/papers/10.1086/521894
- The paper
- Nijland, H. M. J., Ruslami, R., Suroto, A. J., Burger, D. M., Alisjahbana, B., van Crevel, R., & Aarnoutse, R. E. (2007). Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1086/521894
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.